CymaBay Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $31.1M | $1.00B | $0 | — | — | — |
| Operating income | −$101.7M | −$93.1M | −$87.6M | −$52.6M | −$108.2M | −$72.5M |
| Net income | −$105.4M | −$106.0M | −$90.0M | −$51.0M | −$102.8M | −$17.0M |
| Total assets | $434.7M | $141.9M | $202.3M | $153.8M | $205.7M | $186.7M |
| Total liabilities | $142.4M | $105.7M | $69.4M | $11.1M | $19.4M | $16.3M |
| Equity | $292.3M | $36.2M | $132.9M | $142.7M | $186.3M | $170.4M |
| EPS (diluted) | $-0.99 | $-1.21 | $-1.27 | $-0.74 | $-1.53 | $-0.32 |
| Shares out. | 97.3M | 84.7M | 68.9M | 68.9M | 59.5M | 58.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −327.2%
- Net margin
- −339.1%
- Return on equity
- −36.1%
- Return on assets
- −24.2%
- Return on capital (ROCE)
- −25.6%
- Liabilities / assets
- 32.8%
- Debt / equity
- 0.49×
- Book value / share
- $3.00
- Revenue growth (YoY)
- −96.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -1.22distress
- Accruals / assets
- −7.6%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Mcwherter CharlesOfficer — President of R&D | Mar 22, 2024 | D | 15,000 | — |
| Shantharam HarishOfficer — Chief Financial Officer | Mar 22, 2024 | D | 20,125 | — |
| Dickinson KlaraOfficer — Chief Regulatory Officer | Mar 22, 2024 | D | 21,000 | — |
| Quinlan Paul TOfficer — General Counsel | Mar 22, 2024 | D | 41,824 | — |
| Wills Robert JamesDirector | Mar 22, 2024 | D | 30,000 | — |
| Shah SujalOfficer — Chief Executive Officer | Mar 22, 2024 | D | 310,420 | — |
| Emster Kurt VonDirector | Mar 22, 2024 | D | 90,000 | — |
| Shah SujalOfficer — Chief Executive Officer | Mar 13, 2024 | Option exercise | 11,649 | $10.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 22, 2024
- Director / officer changeMar 20, 2024
- Entered a material agreement · Amended charter or bylaws · Regulation FD disclosureFeb 12, 2024
- Director / officer changeJan 26, 2024
- Other material eventDec 21, 2023
- Entered a material agreementDec 13, 2023
- Other material eventSep 12, 2023
- Other material eventSep 11, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.